Vincerx Pharma, Inc.
VINC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.06 | 0.09 | -0.06 | 0.85 |
| FCF Yield | -94.90% | -29.19% | -50.38% | -4.00% |
| EV / EBITDA | -0.72 | -3.27 | -1.77 | -22.02 |
| Quality | ||||
| ROIC | -1,155.03% | -309.34% | -114.55% | -23.64% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.87 | 1.01 | 0.91 | 0.85 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 35.41% | 32.13% | -54.17% | -1,596.36% |
| Safety | ||||
| Net Debt / EBITDA | 0.16 | 0.26 | 0.13 | 2.75 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -996.07 | -1,580.11 | -2,167.46 |